Related Experiment Video
Updated: Jun 20, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
[Hairy cell leukemia: Part I: disease pattern and common therapy]
Jürgen Barth1, Mathias J Rummel
1Medizinische Klinik und Poliklinik IV des Universitätsklinikums Giessen, Klinikstrasse 36, 35385 Giessen. Juergen.Barth@innere.med.uni-giessen.de
Medizinische Monatsschrift Fur Pharmazeuten
|September 8, 2009
Summary
Hairy cell leukemia is a rare B-cell cancer and a subtype of Non-Hodgkin Lymphoma. This article surveys the disease and its available therapeutic options.
Area of Science:
- Hematology
- Oncology
- Immunology
Context:
- Hairy cell leukemia (HCL) is a rare, indolent (low-grade) mature B-cell neoplasm.
- It represents a distinct subtype within the broader category of Non-Hodgkin Lymphoma.
- Understanding HCL is crucial due to its unique clinical and biological characteristics.
Purpose:
- To provide a concise overview of hairy cell leukemia.
- To discuss the current therapeutic strategies for managing HCL.
- To inform clinicians and researchers about the latest treatment advancements.
Summary:
- Hairy cell leukemia is characterized by specific morphological and immunophenotypic features.
- Treatment approaches for HCL have evolved, offering improved outcomes.
- Key therapeutic options include chemotherapy and targeted therapies.
Impact:
- This survey aids in the diagnosis and management of hairy cell leukemia.
- It highlights the importance of tailored therapeutic strategies for rare B-cell malignancies.
- Enhanced understanding can lead to improved patient prognosis and quality of life.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:21Stem Cell Therapy for Tissue Regeneration
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.